Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • August 23rd, 2019 • Hoth Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Exclusive Sublicense Agreement (this “Agreement”) is made effective as of August 19, 2019 (the “Effective Date”) by and between Zylö Therapeutics, Inc., a Delaware corporation with a principal place of business at 200 Patewood Dr., Suite 400C, Greenville, SC 29615 (“Licensor”), and Hoth Therapeutics, Inc., a Nevada corporation with a place of business at 1 Rockefeller Plaza Suite 1039 New York, NY 10020 (“Licensee”). Licensor and Licensee are each hereafter referred to individually as a “Party” and together as the “Parties”.
